Acute myeloid leukemia 4 years after Kaposi's sarcoma in a renal transplant recipient

• Published in: Onkologie Vol. 27; no. 2; p. 163
• Main Authors: Karakus, S, Ozyilkan, O, Akçali, Z, Demirhan, B, Haberal, M
• Format: Journal Article
• Language: English
• Published: Switzerland 01.01.2004
• Subjects: Adult; Female; Graft Rejection - drug therapy; Graft Rejection - prevention & control; Humans; Immunosuppression - adverse effects; Immunosuppressive Agents - adverse effects; Immunosuppressive Agents - therapeutic use; Kidney Transplantation - adverse effects; Leukemia, Myeloid, Acute - diagnosis; Leukemia, Myeloid, Acute - etiology; Sarcoma, Kaposi - diagnosis; Sarcoma, Kaposi - etiology
• ISSN: 0378-584X
• DOI: 10.1159/000076906

Leukemia is a well-known complication of cancer therapy, but development of acute myeloid leukemia (AML) after renal transplantation is rare. Immunosuppressive therapy for organ transplant recipients is complicated by high rates of malignant disease, one condition being Kaposi's sarcoma (KS). A 22-year-old woman developed KS 1 year after renal transplantation, and then developed AML another 4 years later. When KS was diagnosed it was already in extensive stage, and she received ABV combination chemotherapy with doxorubicin plus bleomycin plus vincristine intravenously (i.v.) once daily every 2 weeks. She entered remission but the KS relapsed and 8 cycles of i.v. etoposide monotherapy were given and she re-entered remission. 19 months later, the patient was admitted to hospital with severe malaise, leukocytosis, thrombocytopenia, and anemia. The diagnosis was AML (FABM4). The patient received induction chemotherapy consisting of cytarabine and idarubicin. After completion of this induction therapy she developed neutropenic infection, dyspnea and confusion. Her condition deteriorated rapidly after that, and she died. KS is one of the most common malignancies in renal allograft recipients, whereas AML is a less frequent problem. To our knowledge, this is the first published case of these two different malignancies developing after renal transplantation. The pathogenesis of the AML is discussed.